QQQ   443.02 (+0.92%)
AAPL   178.34 (-1.33%)
MSFT   412.75 (-0.22%)
META   499.59 (+1.93%)
GOOGL   137.57 (-0.64%)
AMZN   177.64 (+0.50%)
TSLA   199.89 (-0.99%)
NVDA   815.10 (+3.03%)
NIO   5.78 (+0.52%)
AMD   198.45 (+3.07%)
BABA   74.75 (+0.97%)
T   16.99 (+0.35%)
F   12.52 (+0.64%)
MU   95.79 (+5.72%)
CGC   3.27 (-0.61%)
GE   158.31 (+0.91%)
DIS   111.37 (-0.19%)
AMC   4.43 (+2.55%)
PFE   26.61 (+0.19%)
PYPL   61.25 (+1.51%)
XOM   106.16 (+1.57%)
QQQ   443.02 (+0.92%)
AAPL   178.34 (-1.33%)
MSFT   412.75 (-0.22%)
META   499.59 (+1.93%)
GOOGL   137.57 (-0.64%)
AMZN   177.64 (+0.50%)
TSLA   199.89 (-0.99%)
NVDA   815.10 (+3.03%)
NIO   5.78 (+0.52%)
AMD   198.45 (+3.07%)
BABA   74.75 (+0.97%)
T   16.99 (+0.35%)
F   12.52 (+0.64%)
MU   95.79 (+5.72%)
CGC   3.27 (-0.61%)
GE   158.31 (+0.91%)
DIS   111.37 (-0.19%)
AMC   4.43 (+2.55%)
PFE   26.61 (+0.19%)
PYPL   61.25 (+1.51%)
XOM   106.16 (+1.57%)
QQQ   443.02 (+0.92%)
AAPL   178.34 (-1.33%)
MSFT   412.75 (-0.22%)
META   499.59 (+1.93%)
GOOGL   137.57 (-0.64%)
AMZN   177.64 (+0.50%)
TSLA   199.89 (-0.99%)
NVDA   815.10 (+3.03%)
NIO   5.78 (+0.52%)
AMD   198.45 (+3.07%)
BABA   74.75 (+0.97%)
T   16.99 (+0.35%)
F   12.52 (+0.64%)
MU   95.79 (+5.72%)
CGC   3.27 (-0.61%)
GE   158.31 (+0.91%)
DIS   111.37 (-0.19%)
AMC   4.43 (+2.55%)
PFE   26.61 (+0.19%)
PYPL   61.25 (+1.51%)
XOM   106.16 (+1.57%)
QQQ   443.02 (+0.92%)
AAPL   178.34 (-1.33%)
MSFT   412.75 (-0.22%)
META   499.59 (+1.93%)
GOOGL   137.57 (-0.64%)
AMZN   177.64 (+0.50%)
TSLA   199.89 (-0.99%)
NVDA   815.10 (+3.03%)
NIO   5.78 (+0.52%)
AMD   198.45 (+3.07%)
BABA   74.75 (+0.97%)
T   16.99 (+0.35%)
F   12.52 (+0.64%)
MU   95.79 (+5.72%)
CGC   3.27 (-0.61%)
GE   158.31 (+0.91%)
DIS   111.37 (-0.19%)
AMC   4.43 (+2.55%)
PFE   26.61 (+0.19%)
PYPL   61.25 (+1.51%)
XOM   106.16 (+1.57%)
NASDAQ:BPTH

Bio-Path (BPTH) Stock Price, News & Analysis

$6.24
+0.16 (+2.63%)
(As of 10:20 AM ET)
Today's Range
$5.96
$6.24
50-Day Range
$5.11
$11.20
52-Week Range
$4.60
$44.80
Volume
1,715 shs
Average Volume
9,293 shs
Market Capitalization
$3.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Bio-Path MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of Bio-Path in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($33.40) to ($20.80) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.16 out of 5 stars


BPTH stock logo

About Bio-Path Stock (NASDAQ:BPTH)

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

BPTH Stock Price History

BPTH Stock News Headlines

The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
Bezos and Gates Invest in Search for Tech's Best-Kept Secret
Billionaires who've made their fortunes in tech, are quietly investing in essential yet rare elements known as "The Seeds of Technology". Learn more about this massive rare earth treasure hunt and the very elements making emerging technologies possible.
StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)
Bio Path Holdings Inc (BPTH)
Bio-Path Holdings Inc.
BPTH Bio-Path Holdings, Inc.
Bio-Path files to sell shares
Bio-Path Holdings Inc
Bio-Path GAAP EPS of -$0.32 beats by $0.02
Bio-Path Hldgs: Q3 Earnings Insights
Preview: Bio-Path Holdings's Earnings
See More Headlines
Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2023
Today
3/01/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BPTH
Fax
N/A
Employees
10
Year Founded
2007

Profitability

Net Income
$-13,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$39.59 per share

Miscellaneous

Free Float
599,000
Market Cap
$3.77 million
Optionable
Optionable
Beta
0.76

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Peter H. Nielsen MBA (Age 75)
    Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer
    Comp: $722.68k
  • Mr. Douglas P. Morris (Age 68)
    Co-Founder, Director of Investor Relations, Secretary & Director
    Comp: $110.68k
  • Mr. Michael Hickey M.B.A.
    VP of Clinical Operations
  • Mr. Anthony Price
    Senior Vice President of Finance, Accounting & Administration
  • Dr. Ana Tari Ashizawa Ph.D.
    MBA, Senior Vice President of Research, Development & Clinical Design














BPTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Path stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BPTH shares.
View BPTH analyst ratings
or view top-rated stocks.

How have BPTH shares performed in 2024?

Bio-Path's stock was trading at $9.26 on January 1st, 2024. Since then, BPTH stock has decreased by 32.6% and is now trading at $6.24.
View the best growth stocks for 2024 here
.

Are investors shorting Bio-Path?

Bio-Path saw a decrease in short interest during the month of February. As of February 15th, there was short interest totaling 19,300 shares, a decrease of 94.9% from the January 31st total of 378,300 shares. Based on an average trading volume of 6,600 shares, the days-to-cover ratio is currently 2.9 days. Currently, 3.1% of the company's shares are short sold.
View Bio-Path's Short Interest
.

When is Bio-Path's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our BPTH earnings forecast
.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) released its quarterly earnings results on Wednesday, November, 15th. The company reported ($6.40) EPS for the quarter, beating analysts' consensus estimates of ($6.80) by $0.40. During the same period in the prior year, the business earned ($9.80) earnings per share.

When did Bio-Path's stock split?

Shares of Bio-Path reverse split on the morning of Friday, February 23rd 2024. The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.19%).
View institutional ownership trends
.

How do I buy shares of Bio-Path?

Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BPTH) was last updated on 3/1/2024 by MarketBeat.com Staff